ReviewCureus2025
A Comprehensive Review of Current Advancements in the Diagnosis, Treatment, and Long-Term Implications of Hypertensive Disorders of Pregnancy.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review aims to analyze the existing data on the diagnosis, risk factors, treatment, prevention, and long-term implications of hypertension in pregnancy. An extensive search was conducted using the PubMed database to identify relevant studies from the past 10 years. These studies indicate that hypertension during pregnancy is a leading cause of maternal and infant mortality in the United States. Early identification of high-risk individuals, along with improved prenatal screening and early intervention strategies, has been shown to enhance maternal care. Home blood pressure monitoring (HBPM) is a simple and reliable method for measuring an individual's blood pressure (BP). Hypertensive disorders of pregnancy can be predicted using biomarkers such as alpha-fetoprotein, free beta-human chorionic gonadotropin (hCG), and D-dimer in blood samples. Additionally, the soluble fms-like tyrosine kinase 1-to-placental growth factor (sFLT-1/PLGF) ratio is a key biomarker for diagnosing early- and late-onset preeclampsia. The administration of antihypertensive medications for mild-to-moderate hypertension is beneficial in preventing adverse maternal and fetal outcomes. First-line (such as labetalol) and second-line (including nifedipine, methyldopa, and hydrochlorothiazides) drugs are commonly used. Aspirin may be used prophylactically in cases of chronic hypertension to prevent preeclampsia. In addition to this, planned delivery at 38 weeks of gestation has been associated with a reduction in adverse outcomes for both mother and fetus. Regular BP monitoring, smoking cessation, and adherence to a healthy diet and lifestyle can help reduce the long-term complications of hypertension during pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.